Azafaros has raised €132 million in an oversubscribed Series B financing round. The funding will support the advancement of its lead clinical-stage asset, AZ-3102, into two Phase 3 trials for the treatment of rare lysosomal storage disorders: GM1 and GM2 gangliosidosis.
This significant milestone marks one of the largest private biotech financings in Europe so far in 2025. The round was led by Forbion Growth and included new investors such as Sofinnova Partners, as well as strategic investor Sarepta Therapeutics, alongside existing investors.
With this financing, Azafaros is poised to accelerate late-stage development of innovative therapies that target multiple neurological symptoms of rare genetic diseases, bringing new hope to patients and families affected by these devastating conditions.
Read more here
A new research collaboration between TNO, Logick Energetics B.V., and InnoSer has officially kicked off at Leiden Bio Science Park, supported by a TKI-LSH grant. The partners...
The Faculty of Science at Leiden University is offering a new opportunity for professionals to deepen their knowledge of data-driven decision-making, complex systems, and...
𝗪𝗵𝗮𝘁 𝗵𝗮𝗽𝗽𝗲𝗻𝘀 𝘄𝗵𝗲𝗻 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝟭𝟱 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗼𝗿𝗴𝗮𝗻𝗶𝘀𝗮𝘁𝗶𝗼𝗻𝘀 𝗼𝗽𝗲𝗻 𝘁𝗵𝗲𝗶𝗿 𝗱𝗼𝗼𝗿𝘀 𝘁𝗼 𝘁𝗵𝗲 𝗽𝘂𝗯𝗹𝗶𝗰? You get an Open Day that brings together over 2,400 visitors, families, students,...